ArticleResearch square2025
Can smartwatches predict migraines?
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: To investigate whether nocturnal autonomic nervous system (ANS) activity and sleep metrics, as measured by a wearable device, can predict the occurrence of next-day migraine in patients with episodic and chronic migraine. Background: The unpredictable nature of migraine episodes contributes to disease burden and limits effective application of tailored preventive strategies. Small-molecule calcitonin-gene-related peptide (CGRP) receptor antagonists, available in limited monthly quantities, are now used for both acute and preventative treatment of migraine. Consequently, improving the ability to identify days with heightened migraine risk could significantly improve migraine management and treatment outcomes. Methods: In this prospective and observational study, adults with migraine (N = 10; 5 with chronic migraine and 5 with episodic migraine) wore the Empatica EmbracePlus Results: Group level predictive performance assessed with LMMs did not reveal significant differences between ANS and sleep metrics on nights prior to no headache days, days with migraine, and days with non-migraine headache. However, individualized models using elastic-net regression, random forests, and gradient boosting machines showed modestly better-than-random AUROCs for next-day migraine prediction in 5/10 participants and next-day headache in 3/10 participants. For next-day migraine prediction models, four of five patients with episodic migraine showed better-than-random AUROCs; no patients with chronic migraine had better-than-random AUROCs. The highest-performing individualized models achieved moderate-to-good performance (AUROC 0.68 for next-day migraine and 0.81 for next-day headache). In highest performing models, SHAP analyses demonstrated sleep duration and a higher minimum PRV influenced next-day migraine and next-day headache probability, while EDA influenced next-day migraine, but not next-day headache. GAM analyses demonstrated that the first three hours after sleep onset and prior to awakening were time periods when PRV and EDA differed prior to a day with migraine or headache in these high performing models. Conclusions: Our findings indicate that applying individualized ML models to wearable-derived autonomic and sleep data may assist in the identification of heightened migraine risk and identified EDA, PRV, and sleep duration as important forecasting features. Our results provide a rationale for future studies that investigate how targeted medication and behavioral interventions on high-risk days may enhance therapeutic precision of migraine treatment and emphasize the importance of defining mechanistic subgroups of patients with migraine most likely to benefit from predictive modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.